Severe influenza patient treated with investigational drug
The announcement was part of a presentation that the company made at the IDWeek 2015 meeting of the Infectious Disease Society of America (IDSA).
Physicians used DAS181 as part of an emergency investigational new drug for a patient with a transplant and a respirator. After receiving the therapy for five consecutive days, the patient’s oxygen requirement decreased. In addition, the patient’s respiratory status enabled the person to be removed from the respirator by the fifth day.
"The potential to impact on multiple respiratory viruses with DAS181 was a major factor in our decision to use the drug, and we were pleased with the rapid response and good clinical outcome for this patient following treatment," Mark Schleiss, professor of pediatrics at the University of Minnesota School of Medicine, said.
Between the second and fourth days of the therapy, the patient’s tracheal aspirate experienced a 60-fold decrease in influenza viral load.
"We were very encouraged by this result, and we are continuing to participate in the ongoing trial of DAS181 for parainfluenza infection, as no effective antiviral treatments are currently licensed for this virus in these high-risk patients," Schleiss said.